首页> 外文期刊>Blood: The Journal of the American Society of Hematology >The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells.
【24h】

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells.

机译:在OCT-1活性低的CML患者中观察到的对伊马替尼的不良反应并非归因于伊马替尼对CD34 +细胞的摄取减少。

获取原文
获取原文并翻译 | 示例
           

摘要

The functional activity of the organic cation transporter 1 (OCT-1) protein in chronic myeloid leukemia (CML) mononuclear cells (MNCs) is highly predictive of molecular response in imatinib treated patients. Here we investigate whether the MNC OCT-1 activity (OA) provides a surrogate indicator of effective targeting of the more immature CD34(+) cells. While confirming our previous findings that high MNC OA is significantly associated with the achievement of major molecular response (MMR; P = .017), the present studies found no relationship between high CD34(+) OA and the achievement of MMR. Furthermore, no correlation was found between the MNC OA and the CD34(+) OA in matched CML samples. These results suggest that the predictive value of the MNC OA may primarily reflect the effective targeting and subsequent reduction of mature CML cells. Therefore kinase inhibition in these mature cells, and not the CD34(+) cells, may be the key determinant of response in CML.
机译:有机阳离子转运蛋白1(OCT-1)蛋白在慢性粒细胞白血病(CML)单核细胞(MNC)中的功能活性高度预测了伊马替尼治疗的患者的分子应答。在这里,我们调查MNC OCT-1活性(OA)是否提供有效靶向更多未成熟的CD34(+)细胞的替代指标。尽管证实了我们先前的发现,即高MNC OA与主要分子应答(MMR; P = .017)的实现显着相关,但本研究发现高CD34(+)OA与MMR的实现之间没有关系。此外,在匹配的CML样本中,在MNC OA和CD34(+)OA之间未发现相关性。这些结果表明,MNC OA的预测价值可能主要反映了成熟CML细胞的有效靶向和随后的减少。因此,在这些成熟细胞而不是CD34(+)细胞中的激酶抑制作用可能是CML反应的关键决定因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号